Broken out by business line, RTI Biologics saw a 7 percent revenue increase for sports medicine ($11.8 million), a 5 percent revenue increase for surgical specialties ($7.9 million) and a 13 percent revenue increase for bone graft substitutes and general orthopedics ($7.9 million).
More Articles on Orthopedic Devices:
New Instrumentation & Partnership for DePuy Synthes Spine
DePuy Synthes Spine Launches Minimally Invasive Posterior-Lateral Fusion System
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
